{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:14Z","timestamp":1786120214906,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/jcp.0b013e31822bb0db","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T15:58:34Z","timestamp":1317743914000},"page":"563-568","source":"Crossref","is-referenced-by-count":23,"title":["Adjunctive Low-Dose Aripiprazole With Standard-Dose Sertraline in Treating Fresh Major Depressive Disorder"],"prefix":"10.1097","volume":"31","author":[{"given":"Chien-Ho","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fong-Lin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4088\/JCP.v63n1102","article-title":"The impact of treatment-resistant depression on health care utilization and costs.","volume":"63","author":"Crown","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","article-title":"What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies.","volume":"116","author":"Fekadu","year":"2009","journal-title":"J Affect Disorder"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4088\/PCC.v08n0506","article-title":"Use of treatment algorithms for depression.","volume":"8","author":"Trivedi","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2009.12.001","article-title":"Accelerating response to antidepressant treatment in depression: a review and clinical suggestions.","volume":"34","author":"Nakajima","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R6-3-20210128","first-page":"57","article-title":"A systematic review of augmentation strategies for patients with major depressive disorder.","volume":"42","author":"Fleurence","year":"2009","journal-title":"Psychopharmacol Bull"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.","volume":"68","author":"Berman","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.","volume":"28","author":"Marcus","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/YCO.0b013e32832a16da","article-title":"Akathisia and second-generation antipsychotic drugs.","volume":"22","author":"Kumar","year":"2009","journal-title":"Curr Opin Psychiatry"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/nedt.2006.2.2.241","article-title":"Dose-dependent rapid-onset akathisia with aripiprazole in patients with schizoaffective disorder.","volume":"2","author":"Basu","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.","volume":"70","author":"Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jad.2009.06.026","article-title":"Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.","volume":"120","author":"Nelson","year":"2010","journal-title":"J Affect Disorder"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: a randomized trial.","volume":"147","author":"Mahmoud","year":"2007","journal-title":"Ann Intern Med"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4088\/PCC.v10n0312e","article-title":"Small doses of aripiprazole augmentation of antidepressant treatment: a report of 3 cases.","volume":"10","author":"Terao","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R20-3-20210128","first-page":"937","article-title":"Augmentation treatment in major depressive disorder: focus on aripiprazole.","volume":"4","author":"Nelson","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.sapharm.2008.08.003","article-title":"The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.","volume":"5","author":"Chen","year":"2009","journal-title":"Res Soc Adm Pharm"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0924-977X(03)00095-6","article-title":"Risk factors and predictors of compliance in depression.","volume":"13","author":"Demyttenaere","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000235977","article-title":"Identifying risk for attrition during treatment for depression.","volume":"78","author":"Warden","year":"2009","journal-title":"Psychother Psychosom"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1185\/030079906X132415","article-title":"Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.","volume":"22","author":"Machado","year":"2006","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201110000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:03Z","timestamp":1786048023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201110000-00003"}},"subtitle":["A Randomized, Double-Blind, Controlled Study"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31822bb0db","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}